Tobias Zeller et al have revealed that checkpoint blockade of CD47 can significantly enhance ADCP in macrophages by blocking the “Don’t Eat Me!” signals.[32] Zhai et al also found that the PD-1 immune checkpoint leads to the elimination of PD-1-positive cancer cells through ADCP and complement-dependent cytotoxicity mechanisms.[33] Given the pivotal role of ADCP in tumor immunotherapy, we further investigated the predictive performance of the ADCP-related signature for response to ICIs. The gene discussed is CD47; the disease is cancer.